Split-thickness skin graft donor site wound healing Skin and Connective Tissue Diseases
Conditions
Interventions
Current interventions as of 01/04/2026:
Perioperative asepsis and sterility of instruments will be ensured. Participants will receive antibiotic prophylaxis with ampicillin 2 g IV one hour before an
Sponsors
Université de Goma
Eligibility
Sex/Gender
All
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: Current key inclusion criteria as of 01/04/2026: 1. Aged 18 to 45 years 2. Requiring split-thickness skin graft 3. Clinically stable 4. Consented to the study 5. Extent of the donor site wound is less than 10% of the body surface area 6. Ability to be followed up until postoperative day 28 _____ Previous key inclusion criteria: 1. Aged 5 to 45 years old 2. Requiring split-thickness skin graft 3. Clinically stable 4. Consented to the study 5. Extent of the donor site wound is less than 10% of the body surface area
Exclusion criteria
Exclusion criteria: Current key exclusion criteria as of 01/04/2026: 1. Mental illness 2. Patients staying less than 6 months in the city 3. History of hypersensitivity reaction to Moringa oleifera derivatives 4. Immunodeficiency state 5. Pregnancy 6. Age below 18 years or over 45 years 7. Patient suffering from condition that may interfere with wound healing: diabetes, renal or hepatic insufficiency, malignant tumor, hypoalbuminemia (serum albumin <4 g/dL), malnutrition, smoking 8. Does not wish to participate in the study 9. Clinical condition deteriorates during the study 10. Decided to stop participating in the study 11. Discontinuation of treatment 12. Death during the study _____ Previous key exclusion criteria: 1. Mental illness 2. Patients staying less than 6 months in the city 3. History of hypersensitivity reaction to Moringa oleifera derivatives 4. Immunodeficiency state 5. Pregnancy 6. Age below 5 years or over 45 years 7. Patient suffering from condition that may interfere with wound healing: diabetes, renal or hepatic insufficiency, malignant tumor, hypoalbuminemia (serum albumin <4 g/dL), malnutrition, smoking 8. Does not wish to participate in the study 9. Clinical condition deteriorates during the study 10. Decided to stop participating in the study 11. Discontinuation of treatment 12. Death during the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Current primary outcome(s) as of 01/04/2026: Mean time to complete wound epithelialization assessed using a sterile transparent plastic measuring guide from the Medline brand and the Bates-Jensen Wound Assessment Tool (BWAT) on Days 7, 10, 13, 16, 20, 24 and 28 _____ Previous primary outcome(s): Time to complete wound epithelialization assessed using a sterile transparent plastic measuring guide from the Medline brand and the Bates-Jensen Wound Assessment Tool (BWAT) on Days 7, 10, 13, 16, 20, 24 and 28 | — |
Secondary
| Measure | Time frame |
|---|---|
| Current key secondary outcome(s) as of 01/04/2026: 1. Wound-related background pain measured using visual analogue scale (VAS) and the Wong-Baker Scale on days 3, 5, 7, 10, 14, 17, 21, and 28. 2. Rate of wound infection measured using culture and sensitivity of wound swab whenever clinical sign of infection is suspected _____ Previous key secondary outcome(s): 1. Wound-related background pain measured using visual analogue scale (VAS) and the Wong-Baker Scale on days 7, 10, 13, 16, 20, 24 and 28 2. Rate of wound infection measured using culture and sensitivity of wound swab whenever clinical sign of infection is suspected 3. Quality of scar measured using the Patient and Observer Scar Assessment Scale (POSAS) at day 28 4. The economic value of the dressing material measured using the Incremental Cost-Effectiveness Ratio (ICER) at complete wound epithelialization | — |
Countries
Congo, Democratic Republic
Contacts
Public ContactTshimbila Kabangu
Outcome results
None listed